RVMD
Revolution Medicines, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Other
- Website revmed.com
- Employees(FY) 338
- ISIN US76155X1000
Performance
+20.36%
1W
+21.11%
1M
+26.98%
3M
+38.98%
6M
+94.8%
YTD
+159.38%
1Y
Profile
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Technical Analysis of RVMD 2024-11-04
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-10-30 16:05
- 2024-10-30 04:05
- 2024-10-25 04:15
- 2024-10-24 16:15
- 2024-10-23 06:00
- 2024-10-22 18:00
- 2024-10-21 16:05
- 2024-10-21 04:05
- 2024-10-07 09:00
- 2024-10-06 21:00
- 2024-08-09 07:14
- 2024-08-07 16:05
- 2024-08-07 04:05
- 2024-07-31 16:05
- 2024-07-31 04:05
- 2024-07-11 12:00
- 2024-07-11 00:00
- 2024-07-09 17:58
- 2024-07-08 16:05
- 2024-07-08 04:05
- 2024-06-14 07:54
- 2024-06-07 21:00
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024(Investorplace)
- 2024-06-05 16:05
- 2024-06-05 04:05
- 2024-06-03 18:00
The 3 Most Undervalued Biotech Stocks to Buy in June 2024(Investorplace)
- 2024-05-10 08:04
- 2024-05-09 03:41
- 2024-05-08 16:02
- 2024-05-08 09:58
- 2024-05-08 04:02
Page 1 of 6
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.